Last reviewed · How we verify
Regional Block 2: QL1
Regional Block 2: QL1 is a Small molecule drug developed by Jennifer Holder-Murray. It is currently in Phase 3 development for Regional anesthesia for surgical procedures. Also known as: Nerve Block.
This drug is used to block nerve signals in a specific region of the body.
Regional Block 2: QL1 is a type of regional block studied in the context of perioperative optimization and postoperative pain management. However, there is not enough information available to determine its specific characteristics or mechanism of action.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Regional Block 2: QL1 |
|---|---|
| Also known as | Nerve Block |
| Sponsor | Jennifer Holder-Murray |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | Phase 3 |
Mechanism of action
Regional Block 2: QL1 works by interrupting the transmission of pain signals from the nerves to the brain, providing temporary pain relief in a targeted area.
Approved indications
- Regional anesthesia for surgical procedures
Common side effects
- Nerve damage
Key clinical trials
- Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data (PHASE3)
- Regional Midazolam in Quadratus Lumborum Block (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Regional Block 2: QL1 CI brief — competitive landscape report
- Regional Block 2: QL1 updates RSS · CI watch RSS
- Jennifer Holder-Murray portfolio CI
Frequently asked questions about Regional Block 2: QL1
What is Regional Block 2: QL1?
How does Regional Block 2: QL1 work?
What is Regional Block 2: QL1 used for?
Who makes Regional Block 2: QL1?
Is Regional Block 2: QL1 also known as anything else?
What development phase is Regional Block 2: QL1 in?
What are the side effects of Regional Block 2: QL1?
Related
- Manufacturer: Jennifer Holder-Murray — full pipeline
- Therapeutic area: All drugs in Anesthesiology
- Indication: Drugs for Regional anesthesia for surgical procedures
- Also known as: Nerve Block
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing